STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug

A clinical trial of daraxonrasib, a pancreatic cancer drug developed by Revolution Medicines, showed patients lived nearly twice as long as those receiving standard chemotherapy. Results were presented at the American Society of Clinical Oncology meeting and published in the New England Journal of Medicine.